title: Morning rise in blood pressure is a predictor of left ventricular hypertrophy in treated hypertensive patients.
abstract: To assess the relationship between home blood pressure and left ventricular mass, we evaluated cardiac echocardiography in 297 hypertensive subjects (188 men and 109 women; mean age, 62.8+/-10.3 years) who were treated with amlodipine monotherapy over 1 year (mean dose, 5.5+/-2.3 mg/day). The morning hypertension group (n=57; 19.2%), who had a morning home systolic blood pressure (HSBP) > or =135 mmHg and an evening HSBP <135 mmHg, had a significantly greater left ventricular mass index (LVMI) concomitant with an increase in the homeostasis model assessment insulin resistance index (HOMA-IR) compared to the good control group (n=174; 58.6%), whose morning and evening HSBP were both <135 mmHg, and had a LVMI roughly equivalent to that of the poor control group (n=63; 21.2%), whose morning and evening HSBP were both > or =135 mmHg. By grouping of subjects according to the difference between morning and evening HSBP (delta HSBP), subjects with a delta HSBP> or =10 mmHg had a significantly greater LVMI than subjects with a delta HSBP <10 mmHg. Increases in LVMI in these patients were still significant after adjustment for age, gender, dose of amlodipine, alcohol consumption, body mass index, office systolic blood pressure, and morning and evening HSBP. In a stepwise multivariate regression analysis, delta HSBP (r2=36.2%, p <0.001), morning HSBP (r2=5.5%, p <0.001), HOMA-IR (r2=1.4%, p=0.016) and age (r2=1.0%, p=0.026) were determined to be significant contributing factors for LVMI. This regression model could explain 44.1% of LVMI variability. These results suggest that morning rise in blood pressure is a dominant predictor of left ventricular hypertrophy.
authors.affiliation: Department of Nephrology, Nippon Telegraph and Telephone Corporation (NTT) Kanto Medical Center, Higashigotanda, Tokyo, Japan. tikeda@tkk.att.ne.jp
authors.forename: Toshio
authors.initials: T
authors.lastname: Ikeda
authors.forename: Tomoko
authors.initials: T
authors.lastname: Gomi
authors.forename: Yuko
authors.initials: Y
authors.lastname: Shibuya
authors.forename: Kiyoko
authors.initials: K
authors.lastname: Matsuo
authors.forename: Takeshi
authors.initials: T
authors.lastname: Kosugi
authors.forename: Nami
authors.initials: N
authors.lastname: Oku
authors.forename: Yuzaburo
authors.initials: Y
authors.lastname: Uetake
authors.forename: Satoshi
authors.initials: S
authors.lastname: Kinugasa
authors.forename: Rie
authors.initials: R
authors.lastname: Furutera
mesh_terms: D000204:Activity Cycles; D000368:Aged; D017311:Amlodipine / Q000627:therapeutic use; D001794:Blood Pressure; D018660:Blood Pressure Monitoring, Ambulatory; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications* / Q000000981:diagnostic imaging / Q000188:drug therapy; D017379:Hypertrophy, Left Ventricular / Q000000981:diagnostic imaging* / Q000453:epidemiology; D007333:Insulin Resistance; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D014463:Ultrasonography
chemical_list: D002121:Calcium Channel Blockers; D017311:Amlodipine